CD8A and neoplasm: CD8+ T cells in the Tcf-1+ stages of differentiation have advanced anti-tumor activity in cellular immunotherapies; Tcf-1-enriched subsets out-persist and out-perform Tcf-1-low/negative subsets in adoptive cell transfer (ACT) [7].